



Anti-Diabetic Properties of the Root Extracts of *Salacia nitida* Benth on Alloxan Induced Diabetic Rats

C. I. Zawua¹ and H. D. Kagbo^{1*}

¹*Department of Pharmacology, Faculty of Basic Medical Sciences, University of Port Harcourt, Rivers State, Nigeria.*

Authors' contributions

This work was carried out in collaboration between both authors. Author CIZ designed the study, performed the statistical analysis, wrote the protocol and wrote the first draft of the manuscript. Authors CIZ and HDK managed the analyses of the study and the literature searches. Both authors read and approved the final manuscript.

Article Information

DOI: 10.9734/EJMP/2018/41430

Editor(s):

- (1) Dr. Elena Maria Varoni, Dipartimento di Scienze Biomediche, Chirurgiche ed Odontoiatriche, University of Milan, Italy.
(2) Dr. Marcello Iriti, Professor, Plant Biology and Pathology, Department of Agricultural and Environmental Sciences, Milan State University, Italy.

Reviewers:

- (1) Yasodha Krishna Janapati, Mekelle University, Ethiopia.
(2) Esraa Ashraf Ahmed ElHawary, Ain Shams University, Egypt.
Complete Peer review History: <http://www.sciencedomain.org/review-history/25583>

Original Research Article

Received 3rd April 2018
Accepted 12th June 2018
Published 17th July 2018

ABSTRACT

Aim: This study was carried out to evaluate the anti-diabetic properties of root extracts of *Salacia nitida* in alloxan-induced diabetic rats.

Study Design: Experimental Animal Study.

Place and Duration of Study: Department of Pharmacology, University of Port Harcourt, Rivers State from July 2016 to February 2017.

Methodology: The study investigated the dose-dependent changes in the blood glucose levels, body weight, serum lipid profile (Total Cholesterol (TC), Total glycerides (TG), Low Density Lipoproteins (LDL) and High Density Lipoproteins (HDL), liver function (serum; Alanine Amino Transferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP), Total Bilirubin, Conjugated Bilirubin, Total Proteins and Albumin) and renal function (serum; creatinine and urea). The method of successive extraction was used, making use of the solvents n-hexane,

*Corresponding author: E-mail: brighthope@rocketmail.com;

dichloromethane, ethyl acetate, methanol and water in order of polarity to extract the root fractions to be utilised for the research. A qualitative phytochemical analysis making use of standardized methods was performed. Acute toxicity was evaluated using the Lorke's method. The anti-diabetic study was evaluated in twenty-one days, comprising two phases: induction phase and treatment phase. Fifty- five rats for the experiment were divided into eleven sets of five rats each.

Results: These results indicate the presence of chemical constituents; alkaloids, saponins, flavonoids, tannins and carbohydrates in the extracts. LD50 value was determined to be more than 5000 mg/kg, which indicates that it is safe. The extracts showed hypoglycemic activity which was evidenced by improving the body imbalance in lipid metabolism experienced during diabetes, restoring body weight to near normal, lowering blood glucose levels, restoring protein levels to near normal, decreased liver glycogen levels, and decreasing albumin, bilirubin, urea and creatinine levels.

Conclusion: This study indicated that the root extracts of *Salacia nitida* showed anti-diabetic properties in alloxan-induced diabetic rats. Thus, the extracts of *S. nitida* will be an inordinate addition to ethnomedicine in the management of diabetes and its complications.

Keywords: Alloxan; *Salacia nitida*; diabetes; blood glucose; lipid profile.

1. INTRODUCTION

The World Health Organization [1] has defined diabetes mellitus as a chronic hyper-glycaemic condition with unsettling disturbances in the metabolism of carbohydrate, fat and protein accompanied by elevated glucose production. It can be regarded as a disorder of metabolism arising from different causes associated with different insulin secretion abnormalities, and/or action[1]. Mention must be made of diabetes as part of the killer diseases that are waging war against the survival, growth, and advancement of human beings globally, because it is a pandemic malady, which can prompt serious complications [2].

Type 2 diabetes is progressively turning into a noteworthy ceaseless disease health burden in Africa. In 2011, about 14 million individuals were evaluated to have diabetes in Africa, and this is projected to ascend to 28 million by 2030[3]. Whether it is T1 or T2 diabetes, those affected are at greater risk of developing complications, thus the need to shield patients from the principal underlying feature, which is persistent hyperglycaemia. Microvascular complications can be defined as retinopathy, which requires photocoagulation, vitreous haemorrhage, lethal or non-lethal renal failure[4]. Apart from fasting hyper-glycaemia, a few organs develop complications in diabetes. The conditions and main organs affected by diabetes are; glycogenosis and dextrinosis and steatohepatitis (liver), atherosclerosis and microangiopathy (blood vessels), retinopathy (eyes), nephropathy (kidneys), neuropathy (cerebrum and peripheral nerves) [5-7]. These harmful effects are isolated into microvascular complications like in the

kidneys, nerves and eye [8] and macrovascular in the blood vessels.

Alloxan (2, 4, 5, 6-tetraoxypyrimidine; 5, 6-deoxy uracil) an acceptable diabetogenic agent for inducing type 2 diabetes in animals [9]. A urea derivative which affects the pancreatic islet beta cells by causing a selective necrosis of it [10].

Even though orthodox drugs which have been accepted worldwide for the management of diabetes are readily accessible, statistics show that a high percentage of these patients' glycemic level have not been maintained in line with the treatment goals as endorsed by international diabetic associations [11-12]. These agents such as sulphonylurea and biguanide are related with extreme adverse effects; lactic acidosis, hypoglycaemia [13]. Therefore, the use of trado-medicine as an adjunct is fast gaining significance in the treatment of the disease. Nevertheless, alternatives to the already existing synthesized drugs are now sought for worldwide, as a result of the perceived cost-effectiveness, assumed lesser toxicity, and minimal or no reported side effects unlike the clinically approved drugs which are used for diabetes mellitus treatment [14]. Reports have shown that most plants used for diabetes management contains alkaloids, carotenoids, flavonoids, glycosides, terpenoids, and many others, that are as often as possible thought to have anti-diabetic impact [15] and free from adverse reactions than the manufactured medicines[14]. Therapeutic plants have been accounted to have hypoglycemic actions, which enhance insulin secretion, glucose uptake by adipose tissues. They also enhance the production of glucose in the liver and its absorption from the intestine [16].

An example of such plants is *Sarcopoterium spinosum* [17]. Another is *Salacia nitida* Benth.

Salacia nitida is a genus of plants in the Celastraceae family. It is a woody climbing shrub distributed in Sri-Lanka, South-West India, Thailand, Philippines, Java [18] South Africa and Southeastern part of Nigeria. In the southern part of Nigeria amongst the Ogonis, a decoction of roots of *Salacia nitida* serve as useful antimalarial agent [19]. The present study investigated the dose-dependent changes in the blood glucose levels, body weight, serum lipid profile (TC, TG, LDL and HDL), liver function (serum; ALT, AST, ALP, Total Bilirubin, Conjugated Bilirubin, Total Proteins and Albumin) and renal function (serum; creatinine and urea) in normal and alloxan-induced diabetic rats for a period of 3 weeks of the root extracts of *Salacia nitida*.

2. MATERIALS AND METHODS

2.1 Plant Material

The fresh root of *Salacia nitida* plant used in this study was obtained from a local area in Omuokiri of Aluu, Rivers, Nigeria. The plant was identified and validated. The herbarium number is UPHCO288. The roots were washed and reduced to smaller sizes and air-dried to a constant weight and then ground into powder using a grinder machine (manufactured from Indore).

2.2 Preparation of Extracts

About 1850 g of the powdered root was sequentially extracted using extraction solvent by maceration for three (3) days. The extraction was done with five (5) different solvents in their increasing order of polarity. The solvents used include n-hexane, dichloromethane, ethyl-acetate, methanol and water with regular shaking at room temperature (28°C). Each time, the plant material was filtered through Whatmann filter paper number: 45 then dried and later extracted with each of the five solvents. Each of the extracts was then carefully evaporated to dryness over a water bath under controlled temperature, afterwards was stored in the refrigerator and then used for further experimental study.

2.3 Animals

Fifty five (55) Adult Wistar rats males and females, were weighed (100-250 g). They were

obtained from the Faculty of Pharmaceutical Sciences, animal house of the University of Port Harcourt and were kept in the animal house of the Faculty at room temperature and relative humidity and a 12:12 h light/ dark cycle for one week. The wood shavings (sawdust) were changed daily and the cages washed and cleaned each other day. They were allowed to become familiar with laboratory conditions for 7 days before the start of the study. The endorsement of the Animal Ethical Committee of University of Port Harcourt was sought before the start of the analyses. Every one of the protocols and investigations were led in consistency with the ethical standards and rules.

2.4 Phytochemical Evaluation

Standard method for phytochemical screening were carried out to determine the presence of Alkaloids, saponins, flavonoids, triterpenoids, tannins and reducing sugars [20,21,22,23].

2.5 Acute Toxicity Study

Acute toxicity was carried out on the experimental animals making use of method of Lorke [24]. It was carried out to determine the safety profile of the plant.

2.6 Anti-diabetic Activity

2.6.1 Experimental Induction of diabetes

Induction of diabetes in the animals was carried out after an overnight fast (12 hours) by an intraperitoneal injection of alloxan at 150 mg kg⁻¹ b.wt. Calculations were done and then it was solubilized using 100ml of saline solution before injection [25]. After an hour of the administration, the animals were fed *ad libitum* and 5% dextrose solution was given to them in feeding bottles for 24 hours to overcome the early hypoglycaemic stage. The animals were then watched for 72 hours after which blood samples were collected by the clipping of the tail and blood glucose levels then evaluated. A group was chosen randomly to represent the control group, which received saline alone. The rats whose glucose level >150 mg/dl were separated into groups of 5 rats each for further experimental study [26,27].

2.7 Experimental Design

Eleven groups of animals containing five rats each was divided as follows;

Group I: Saline (untreated/ normal control)

Group II: Hyperglycaemic rats- Diabetic control (Normal saline)

Group III: Hyperglycaemic rats + Glibenclamide (10 mg/kg/day p.o. once daily)

Group IV: Hyperglycaemic rats + dichloromethane extract of *Salacia nitida* root ;(250 mg/kg/b.wtp.o once daily)

Group V: Hyperglycaemic rats + dichloromethane e extract of *Salacia nitida* root; (500 mg/kg/b.wtp.o once daily)

Group VI: Hyperglycemic rats + ethyl acetate extract of *Salacia nitida* root (250 mg/kg/b.wtp.o once daily)

Group VII: Hyperglycemic rats + ethyl acetate extract of *Salacia nitida* root (500 mg/kg/b.wtp.o once daily)

Group VIII: Hyperglycemic rats + methanol extract of *Salacia nitida* root (250 mg/kg/b.wtp.o once daily)

Group IX: Hyperglycemic rats + methanol extract of *Salacia nitida* root (500 mg/kg/b.at p.o once daily)

Group X: Hyperglycemic rats + aqueous extract of *Salacia nitida* root (250 mg/kg/b.wtp.o once daily)

Group XI: Hyperglycemic rats + aqueous extract of *Salacia nitida* root (500 mg/kg/b.wtp.o once daily)

The diabetic rats' BGLs were monitored by making small incisions on their tail and collecting blood into the available test-kit (Accu-Check Active Test Meter, Roche Diagnostics). The animals were weighed on day 0, 3, 7, 14 and 21 after 1h of treatment with the extracts and the standard anti-diabetic drug (Glibenclamide); making use of the weighing balance (GmbH, Mannheim, Germany). The drug and extracts administration was carried out for a period of 21 days using orogastric tube.

2.8 Determination of Biochemical Parameters

On day 21 of treatment with *S. nitida* extracts, the animals were sacrificed under ether anaesthesia, blood samples were then collected. The Biochemical Parameters Evaluated were Low Density Lipoproteins (LDL), High Density Lipoproteins (HDL), Triglycerides, Urea, Creatinine, Aspartate Aminotransferase (AST), Alanine Amino Transferase (ALT), Alkaline Phosphatase (ALP), Albumin, Bilirubin and total proteins. Serum urea was determined using the procedure of [28] and creatinine determined

using the procedure of [29] Serum aspartate and alanine aminotransferase (AST and ALT) were evaluated making use of the method of [30]. [31] method was used to evaluate alkaline phosphate (ALP) level, while albumin level was evaluated using the BCG Assay kit [32]. The TC, TG, HDL-C and LDL-C levels were evaluated in the serum of the animals using standard procedures [33].

2.9 Statistical Analysis

Statistical analysis of results was done using SPSS version 20.0. Results were presented as Mean±Standard Error of Mean. ANOVA followed by the LSD (Least Significant Difference), were used to determine significant differences across the groups. The differences in the mean values of the groups were the criteria for the pharmacological activities. The difference in means was considered significant at $p \leq 0.05$.

3. RESULTS AND DISCUSSION

3.1 Phytochemical Analysis

Preliminary phytochemical screening indicated the presence of alkaloids (except in dichloromethane and ethyl acetate extracts), saponins, flavonoids and tannins.

3.2 Acute Toxicity Studies

The acute toxicity study in rats produced no death or signs of toxicity even at high dose (5000 mg/kg body weight). Thus, the LD₅₀ value was found to be 5000 mg/kg.

3.3 Antidiabetic Activity

Table 3 and Table 4 shows the effect of oral administration of the root extracts of *S. nitida* and glibenclamide on body weight, Table 5 and 6 on blood glucose level respectively of alloxan-induced diabetic rats for the period of the study. There was a significant ($p < 0.05$) decrease in the body weight and also hyperglycaemia on day 3 in the alloxan-induced diabetic rats when compared to the normal rats. On administration of the extracts and glibenclamide, there was a significant ($p < 0.05$) increase in the body weight from day 7 with a maximal increase achieved on day 21 by the 500 mg dose of ethyl acetate. Similarly, the 500 mg dose of aqueous extract caused a maximal reduction in blood glucose level by day 21.

Table 1. Phytochemical screening results

Crude extract test	Dichloromethane	Ethyl acetate	Methanol	Aqueous
Alkaloids	—	—	+	+
Saponins	+	+	+	+
Flavonoids	+	+	+	+
Tannins	+	+	+	+
Carbohydrates	+	+	+	+
Reducing sugars	—	+	+	+
Anthraquinones	+	—	—	—

+ = present; — = absent

3.4 Effect of the Root Extracts on the Body Weight

Table 3 and Table 4 shows the effect of oral administration of the root extracts of *S.nitida* and glibenclamide on body weight.

3.5 Change in Body Weight

Table 4 shows that at the end of the study period, administration of the methanol 250 mg and ethyl acetate 500 mg extracts had the most significant increase in body weight.

3.6 Effect of the Root extracts on Blood Glucose Level

Table 5 and 6 showed that at the end of the study period, the Aqueous extract 500mg and Methanol 250mg extracts caused a decrease in blood glucose levels which can compared to the standard drug (glibenclamide).

3.7 Effects of the Root Extracts on the Lipid Function Tests

Lipid profile: the analysis of various lipid parameters are seen in Table 7, it shows the effect of oral administration of the root extracts of *S.nitida* and glibenclamide on the lipid function tests [total cholesterol (TC), total glycerides (TG), high density lipoprotein (HDL), low density lipoprotein (LDL)] of alloxan-induced diabetic rats for the period of the study. The TC, TG, and LDL-

C levels significantly decreased ($p < 0.05$) while there was a significant ($p < 0.05$) increase in the HDL-C levels following the treatment of the rats with the extracts. The administration of the aqueous extracts produced significant effect relative to the untreated group for the serum TG and TC levels

3.8 Effects of the Root Extracts on Liver Function Tests

There was an observable elevation of the liver enzymes AST, ALT and ALP, which was markedly noticed in the untreated rats and diabetic rats before the extracts administration; however, following administration of the aqueous extracts, the liver enzymes level significantly ($p < 0.05$) decreased. On administration of the extracts aqueous (500 mg & 250 mg), methanol (500 mg & 250 mg) and dichloromethane (250 mg), there was a significant ($p < 0.05$) decrease in the Total bilirubin (T.B) levels when compared to the groups that were untreated with the most significant effect seen with the aqueous extracts. There was also a significant ($p < 0.05$) decrease in the Conjugated bilirubin (CB) levels on the administration of the dichloromethane 500 mg. The Total protein (TP) levels on the administration of the extract ethyl acetate 500mg showed a significant ($p < 0.05$) increase compared to the groups that were untreated. There was no significant change seen on the administration of the extracts on Albumin levels relative to the untreated group.

Table 2. Response and effect on the rats treated with various doses of the extract of the root of *Salacia nitida*

Dose (mg/kg)	No of rats	Survival	Death
10	3	3	0
100	3	3	0
1000	3	3	0
1600	3	3	0
2900	3	3	0
5000	3	3	0

Table 3. Effect of the root extracts on the body weight

Treatment groups (/kg daily)	Day 0	Day 3	Day7	Day 14	Day 21
Normal	227.30±1.22	226.63±1.84	240.50±3.18	249.57±1.44	251.33±3.38
Diabetic Control	116.10±1.19	111.75±1.03	110.75±1.49	108.75±1.93	107.18±2.82
Glibenclamide10 mg	169.10±12.79	124.14±6.58 ^a	141.30±12.00 ^a	156.86±15.48 ^a	157.40±17.10 ^a
Aqueous extract 500 mg	100.00±0.00	83.33±8.82 ^a	103.33±3.33 ^a	113.33±8.82 ^a	116.67±6.67 ^a
Aqueous extract 250 mg	146.67±13.33	110.00±20.82 ^a	116.67±20.28 ^a	120.00±17.32 ^a	120.00±17.32 ^a
Methanol extract 500 mg	150.00±0.00	133.33±8.82 ^a	143.33±6.67 ^a	146.66±13.33 ^a	146.67±13.33 ^a
Methanol extract 250 mg	107.50±4.79	107.50±7.50 ^a	117.50±2.50 ^a	127.50±2.50 ^a	140.00±9.13 ^a
Dichloromethane extract 500 mg	134.87±6.69	135.47±13.83 ^a	136.70±5.59 ^a	150.93±8.48 ^a	145.53±2.21 ^a
Dichloromethane extract 250 mg	163.45±6.47	143.98±12.18 ^a	148.78±8.71 ^a	164.78±10.04 ^a	156.78±3.44 ^a
Ethyl acetate extract 500 mg	131.40±9.90	130.05±5.35 ^a	122.15±2.05 ^a	164.40±14.70 ^a	184.95±5.05 ^a
Ethyl acetate extract 250 mg	170.35±20.25	140.50±0.50 ^a	146.60±1.50 ^a	128.85±8.55 ^a	129.15±8.45 ^a

Data represented as Mean± SEM (Standard error of mean) (n=5)^a Significant values when compared with the diabetic control p<0.05(ANOVA)

Table 4. Effect of oral administration of the root extracts *S. nitida* and glibenclamide on body weight

Treatment groups (/kg daily)	Body Weight (gm)	
	Initial	Final
Normal	227.30±1.22	242.01±2.46
Diabetic Control	116.10±1.19	109.60±1.86
Glibenclamide10mg	169.10±12.79	144.93±12.79 ^a
Aqueous extract 500 mg	100.00±0.00	104.17±6.91 ^a
Aqueous extract 250 mg	146.67±13.33	116.67±18.94 ^a
Methanol extract 500 mg	150.00±0.00	142.50±10.54 ^a
Methanol extract 250 mg	107.50±4.79	123.13±5.41 ^a
Dichloromethane extract 500 mg	134.87±6.69	142.16±7.53 ^a
Dichloromethane extract 250 mg	163.45±6.47	153.58±8.59 ^a
Ethyl acetate extract 500 mg	131.40±9.90	150.39±6.79 ^a
Ethyl acetate extract 250 mg	170.35±20.25	136.28±4.75 ^a

Data represented as Mean± SEM (Standard error of mean) (n=5)^a Significant values when compared with the diabetic control p<0.05(ANOVA)

Table 5. Effect of oral administration of the root extracts of *S. nitida* and glibenclamide on Blood Glucose Level (BGL)

Treatment groups(/kg body weight daily)	Day 0(mg/dl)	Day3(mg/dl)	Day7(mg/dl)	Day 14(mg/dl)	Day 21(mg/dl)
Normal	97.00±2.08	90.00±34.12	87.67±2.03	79.33±1.45	103.33±2.40
Diabetic Control	66.25±8.05	299.50±23.67	350.00±16.63	363.75±14.14	480.25±39.06
Glibenclamide10 mg	84.60±9.14	768.40±111.60 ^a	709.80±109.34 ^a	452.40±54.81 ^a	348.40±68.95 ^a
Aqueous extract 500 mg	54.00±4.51	627.00±131.87 ^a	509.00±38.89 ^a	457.33±72.22 ^a	317.00±16.09 ^a
Aqueous extract 250 mg	71.67±4.06	481.33±24.90 ^a	467.67±19.10 ^a	500.67±16.91 ^a	441.33±35.47 ^a
Methanol extract 500 mg	57.67±4.48	497.00±205.58 ^a	280.67±115.57 ^a	303.33±99.35 ^a	300.33±103.64 ^a
Methanol extract 250 mg	60.25±8.72	655.25±132.91 ^a	348.75±81.92 ^a	455.50±155.32 ^a	349.00±78.04 ^a
Dichloromethane extract 500 mg	76.33±9.13	414.67±17.90 ^a	337.67±14.05 ^a	516.33±41.25 ^a	328.00±44.41 ^a
Dichloromethane extract 250 mg	74.50±6.36	594.25±98.89 ^a	574.25±108.92 ^a	549.00±110.36 ^a	460.00±47.21 ^a
Ethyl acetate extract500 mg	99.00±1.00	401.50±53.50 ^a	655.00±225.00 ^a	306.00±171.00 ^a	277.50±157.50 ^a
Ethyl acetate extract 250 mg	99.00±1.00	653.00±227.00 ^a	404.00±73.00 ^a	418.50±33.50 ^a	388.50±58.50 ^a

Data represented as Mean± SEM (Standard Error of Mean) (n=5) significant values when compared with diabetic control p<0.05(ANOVA)

Table 6. Change in Blood Glucose Level (BGL)

Treatment groups(/kg body weight daily)	Day3	Day21	%MAX.RED
Diabetic Control	299.50±23.67	480.25±39.06	-1.81
Glibenclamide10 mg	768.40±111.60 ^a	348.40±68.95 ^a	4.20
Aqueous extract 500 mg	627.00±131.87 ^a	317.00±16.09 ^a	3.10
Aqueous extract 250 mg	481.33±24.90 ^a	441.33±35.47 ^a	0.40
Methanol extract 500 mg	497.00±205.58 ^a	300.33±103.64 ^a	1.97
Methanol extract 250 mg	655.25±132.91 ^a	349.00±78.04 ^a	3.06
Dichloromethane extract 500 mg	414.67±17.90 ^a	328.00±44.41 ^a	0.86
Dichloromethane extract 250 mg	594.25±98.89 ^a	460.00±47.21 ^a	1.34
Ethyl acetate extract 500 mg	401.50±53.50 ^a	277.50±157.50 ^a	1.24
Ethyl acetate extract 250 mg	653.00±227.00 ^a	388.50±58.50 ^a	2.65

Data represented as Mean± SEM (Standard Error of Mean) (n=5) significant values when compared with diabetic control p<0.05(ANOVA)

Table 7. Effect of oral administration of the root extracts of *S. nitida* and glibenclamide on the lipid function tests

Group(/kg body weight daily)	TC	TG	HDL	LDL
Normal	1.73±0.09	1.04±0.12	0.56±0.02	0.67±0.09
Diabetic Control	2.38±0.13	1.22±0.10	0.85±0.05	0.95±0.14
Glibenclamide10 mg	2.26±0.09	1.19±0.08	0.83±0.06	0.88±0.11
Aqueous 500 mg	1.97±0.03 ^a	0.68±0.04 ^a	0.64±0.04	1.03±0.03
Aqueous 250 mg	1.80±0.06 ^a	0.65±0.03 ^a	0.50±0.04	1.03±0.09
Methanol 500 mg	1.83±0.07 ^a	0.90±0.17 ^a	0.60±0.05	0.83±0.07 ^a
Methanol 250 mg	2.10±0.07 ^a	0.84±0.03 ^a	0.66±0.04	1.05±0.03
Dichloromethane 500 mg	2.17±0.35 ^a	1.53±0.35	0.68±0.12	0.83±0.13 ^a
Dichloromethane 250 mg	2.10±0.16 ^a	1.19±0.08 ^a	0.51±0.08	0.98±0.13
Ethyl acetate 500 mg	2.40±0.10	1.71±0.41	0.72±0.10 ^a	0.90±0.20 ^a
Ethyl acetate 250 mg	3.00±0.40	1.16±0.10 ^a	0.80±0.12 ^a	1.50±0.10

Data represented as Mean± SEM (Standard error of the mean) (n=5)^a Significant values when compared with diabetic control p<0.05(ANOVA).

Table 8. Effect of oral administration of the root extracts of *S. nitida* and glibenclamide on the liver function tests

Group(/kg body weight daily)	AST	ALT	ALP
Normal	195.67±1.67	45.67±0.88	234.33±3.84
Diabetic Control	238.00±16.72	59.25±6.42	780.00±159.58
Glibenclamide10 mg	220.00±13.24	59.40±5.96	594.60±84.92
Aqueous extract 500 mg	56.33±23.92 ^a	49.33±23.17 ^a	751.33±60.88 ^a
Aqueous extract 250 mg	25.00±20.50 ^a	19.00±17.50 ^a	431.67±168.38 ^a
Methanol extract 500 mg	74.67±41.70 ^a	29.00±13.32 ^a	414.67±141.24 ^a
Methanol extract 250 mg	75.25±14.83 ^a	50.75±15.12 ^a	352.25±92.70 ^a
Dichloromethane extract 500 mg	291.00±67.31	106.00±36.67	1191.33±362.21
Dichloromethane extract 250 mg	242.75±66.77	229.25±74.58	1831.75±340.97
Ethyl acetate extract 500 mg	211.50±71.50 ^a	261.00±177.00	1584.50±307.50
Ethyl acetate extract 250 mg	173.50±0.50 ^a	54.00±4.00 ^a	490.50±117.50 ^a

Data represented as Mean± SEM (Standard error of the mean)(n=5) Significant values when compared with diabetic control p<0.05(ANOVA).

Table 9. Effect of oral administration of the root extracts of *S. nitida* and glibenclamide on the liver function tests

Group(/kg body weight daily)	TB	CB	TP	ALB
Normal	4.30±0.10	0.73±0.09	71.67±2.19	35.00±3.21
Diabetic Control	4.10±0.18	0.98±0.15	77.25±1.38	34.25±1.25
Glibenclamide 10 mg	4.06±0.18	0.84±0.05	74.60±2.48	32.80±0.97
Aqueous extract 500 mg	2.87±0.18 ^a	1.67±0.09	70.00±4.73 ^a	30.67±0.67
Aqueous extract 250 mg	2.20±0.31 ^a	1.73±0.09	69.67±6.17 ^a	28.67±2.33
Methanol extract 500 mg	2.97±0.22 ^a	2.57±0.03	72.67±1.33 ^a	28.00±0.57
Methanol extract 250 mg	3.43±0.27 ^a	2.70±0.11	70.25±1.11 ^a	29.25±0.48
Dichloromethane extract 500 mg	4.73±0.37	0.63±0.29 ^a	74.67±3.93 ^a	32.67±2.17
Dichloromethane extract 250 mg	4.08±0.19 ^a	0.98±0.09	74.75±3.09 ^a	34.00±2.08
Ethyl acetate extract 500 mg	4.10±0.20	0.95±0.15	82.00±1.00 ^a	31.00±1.00
Ethyl acetate extract 250 mg	4.30±0.30	1.05±0.05	70.50±1.50 ^a	33.00±1.00

Data represented as Mean± SEM (Standard error of the mean) (n=5)^a Significant values when compared with diabetic control p<0.05(ANOVA).

3.9 Effects of the root extracts on kidney function tests

Table 10 shows the effect of oral administration of the root extracts of *S. nitida* and glibenclamide on the kidney function tests (urea, creatinine) of alloxan-induced diabetic rats for the period of the study. It was observed that for the untreated diabetic rats there were elevated levels of serum urea, and creatinine but on the administration of the aqueous and methanol extracts there was significant (p<0.05) decrease in the creatinine levels.

4. DISCUSSION

Diabetes mellitus management has globally remained despite the easy accessibility to synthetic agents and insulin. There are presently now quite some medicinal plants which are promising alternatives to conventional drugs and may be utilised in the treatment of this endless ailment because of their anti-glycaemic activity

and minimal side effects. One of such plants is *Salacia nitida*. The preliminary phytochemical screening of the root extracts of *Salacia nitida* indicated that flavonoids, saponins, reducing sugars (except in the dichloromethane extract) and tannins were present. These compounds from studies have been reported to possess various biological actions and functions [34-36]. This finding was in agreement with studies in literature [37-39].

The World Health Organization has advocated for the determination of the safety profile of medicinal plants to standardise their use [40]. This prompted the acute toxicity study of the root extracts of *Salacia nitida*, and it was discovered to be greater than 5000 mg/kg body weight as no animal died. This finding suggests a high safety profile of *S. nitida* root extracts which makes it an excellent choice for use in the management of chronic diseases such as diabetes mellitus. This finding is similar to a study by [39].

Table 10. Effect of oral administration of the root extracts of *S. nitida* and glibenclamide on the kidney function tests

Group(/kg body weight daily)	Urea	Creatinine
Normal	7.50±0.23	220.33±0.88
Diabetic Control	5.05±1.09	235.75±109.78
Glibenclamide 10 mg	6.62±0.55	144.20±19.64
Aqueous extract 500 mg	9.60±1.49	52.00±4.00
Aqueous extract 250 mg	15.17±2.10	65.33±8.35
Methanol extract 500 mg	6.53±0.59	50.33±7.69
Methanol extract 250 mg	7.95±1.66	56.00±3.94
Dichloromethane extract 500 mg	12.33±2.07	285.00±85.59 ^a
Dichloromethane extract 250 mg	14.15±1.44	199.00±55.02
Ethyl acetate extract 500 mg	12.40±2.80	162.00±45.00
Ethyl acetate extract 250 mg	9.20±4.50	132.00±44.00

Data represented as Mean± SEM (Standard error of the mean) (n=5)^a Significant values when compared with diabetic control p<0.05(ANOVA).

In the present study, on day 3, the blood sugar level in the diabetic rats after induction of diabetes by alloxan was observed to rise significantly. Alloxan brings about a diminution in insulin secretion by the destruction of β -cells of the islets of Langerhans, and a substantial increase in the cytosolic calcium concentration which induces further destruction of pancreatic islet cells [41-43], this situation led to insulin insufficiency and caused an elevation of the blood glucose, triglyceride and total cholesterol level [44].

S. nitida extracts significantly lowered the blood glucose level of the treated rats from the 7th day of administration at different doses when compared to the untreated group. The observed changes are indications of the hypoglycaemic and anti-hyperglycaemic effects of *S. nitida*, which is comparable to that of other studies [45-47].

The maximal blood glucose lowering activity which was higher than that of glibenclamide was seen at the 500mg dose of aqueous extract. The extracts contain bioflavonoids and saponins which have been reported to have hypoglycaemic effect in diabetic animal models [48-49]. So also does the presence of phenols as in *V. persica* phenolic-rich extracts which revealed an excellent diabetic control when compared to orthodox anti-diabetic agents [50]. The potential mechanism of action of this medicinal plant is likely to be associated with pancreatic β -cell regeneration [51-56].

One of the significant complexities of type I diabetes is weight loss which arises as a result of the reduction in insulin activity which is required for the conversion of glucose into glycogen and break down of fats; there is also the inhibition of lipolysis due to its unavailability because of destruction in beta cells [57]. Alloxan-induced weight loss mimics that of diabetes as was noticed from the results on the 3rd day. However, on commencement of treatment with *Salacia nitida* extracts, the body weight significantly improved from day 7 when compared to the diabetic rats that did not receive the extracts. The finding suggests that the extracts had blood glucose lowering ability by potentiating glucose metabolism which may be as a result of the extract action on muscle tissues, controlling their wasting and this can be achieved through reversed gluconeogenesis [58]. However, of all the treatments, the methanol 250mg and ethyl acetate 500 mg/kg dose restored the weight

towards normal. Thus, *Salacia nitida* might be used to control body weight in people with diabetes. [59] noted ethanol cardamom leaves extract (ECLE) contains flavonoids, which serves to control body weight. *Salacia nitida* extracts also contain flavonoids, which may explain the extracts ability to regulate body weights. This finding is similar to results in [39].

One of the challenges discerned among diabetic patients is the presence of compound comorbidities which predisposes the patient to several incidences of drug interactions as a result of polypharmacy. Thus, herbs which possess the ability to affect several metabolic targets are being sorted after such as the herb *Brassica napus* and *Boswellia Serrata* gum resin which has shown positive effects on lipid profile as well as antihyperglycaemic effects in these patients [60, 61]. *S. nitida* has also demonstrated its lipid-lowering properties in addition to its blood glucose lowering properties this may be attributed to the rich phytochemicals such as saponins and tannins; as studies have shown they exert a positive effect on dyslipidemia [62-63]. Flavonoids from plants have been implicated in the reduction of lipids by [64-66] inhibition of HMG-CoA reductase. It, therefore, follows that the underlying mechanism of fat lowering effect of the *Salacia nitida* extracts could be by inhibition of lipid absorption due to [67] the presence of saponins, flavonoids and tannins.

The liver plays a dominant role in the entire body glucose homeostasis. It is the organ responsible for facilitating de-novo glucose production [68]. Insulin secretion in normal physiological conditions activates signalling pathways which leads to the excretion of more glucose and more uptake of glucose to the required tissues, also the activation of anabolic pathways which aids glycogen synthesis in liver and muscles, and the inhibition of hepatic gluconeogenesis. Hyperglycemia results therefore from the concomitant disorders in insulin action which results from both low glucose disposal and unrepressed glucose production. Assay for liver enzymes namely Alkaline Phosphatase, Aspartate aminotransferase and Alanine transaminase is critical in evaluating ideal liver capacity amid diabetes, when the levels are elevated, it is an indication of liver dysfunction [69], there was observable elevation of the liver enzymes, which was markedly noticed in the untreated rats and diabetic rats before the extracts administration; however following

administration, the liver enzyme levels significantly reduced.

Therefore, this increased serum enzyme levels in the untreated diabetic rats confirms damage to the plasma membrane, leading to a compromise of membrane integrity but its absence in the treated is suggestive of the extracts cellular membrane and hepatocellular protective effects of the plant extract [70,71]. These seeming hepatic protective activities of the extracts are indicative that once-daily chronic application may not necessarily predispose to hepatic toxicity. The comparable observation was likewise detailed in [72,73].

An increase in tissue or serum bilirubin concentration results in jaundice, and it occurs in toxic or infectious disease of the liver, e.g. hepatitis [74]. After the 21 days of treatment, both total and conjugated bilirubin was significantly decreased, and it is an indication of protective haemoglobin metabolism and liver function of the treated rats. Studies on experimental animals have shown a significant relationship between insulin deficiency and metabolic distortion such as the excessive breakdown of proteins and amino acids leading to decreased protein content [75]. Administration of the extracts restored the protein levels to near normal levels. In this study, the albumin levels of the group treated with the extracts were not significantly different from the diabetic group that did not receive the extracts. The liver's function to synthesise albumin and globulin is decreased in the light of its dysfunction [76], and it is an indication of hepatitis and liver cirrhosis (liver damage).

Diabetic nephropathy was observed in the untreated diabetic rats with elevated levels of serum protein, urea, and creatinine. The creatinine levels were found to have significantly decreased following the administration of the aqueous and methanol extract.

5. CONCLUSION

Oral administration of the aqueous, dichloromethane, methanol and ethyl acetate extracts of *Salacia nitida* Benth showed hypoglycemic activity in alloxan-induced diabetes in experimental Wistar rats which was evidenced by improving the body imbalance in lipid metabolism experienced during diabetes, restoring body weight to near normal, decreased liver glycogen levels, and decreasing albumin,

bilirubin, urea and creatinine levels. Further research to determine the particular compounds responsible for the anti-diabetic property in the extracts should be studied. A combination of the extracts (especially the ethyl acetate and aqueous extracts) may have additive effects which could likely lead to enhanced prevention and treatment of diabetes in humans.

CONSENT

It is not applicable.

ETHICAL APPROVAL

As per international standard or university standard, written approval of Ethics committee has been collected and preserved by the authors.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. World Health Organization, Geneva Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus. 1999. Report Number: WHO/NCD/NCS/99.2; 1999.
2. HarandeYahya Ibrahim. Exploring the literature of diabetes in Nigeria: A bibliometric study. AJDM. 2011;19(2):8-11.
3. International Diabetes Federation: IDF Diabetes Atlas. Key findings .5th edition. Brussels, Belgium: IDF; 2011;46-47
4. Watkins P.J. ABC of Diabetes 5th edition, BMJ publishing, Tavistocksquare, London; 2003;43.
5. Guyton WF, Hall EJ. Textbook of medical physiology. 10th ed. Vol 20. New York: Lange Medical books. Endocrine Functions of the Pancreas and Regulation of Carbohydrate Metabolism. 2002;332.
6. Salehi I, Farajnia S, Mohammadi M, Sabouri Gannad M. The pattern of brain-derived neurotrophic factor gene expression in the hippocampus of diabetic rats. IJBMS. 2010;13:146-153.
7. Zare K, Tabatabaei SR, Shahriari A, Jafari RA. The effect of butter oil on avoidance memory in normal and diabetic rats. IJBM. 2012;15:983-989.

8. Fowler Michael, J. Clinical Diabetes: 2008; 26(2):77-81.
Available:(<http://clinical.diabetesjournals.org>)
9. Viana GS, Medeiros AC, Lacerda AM, Leal LK, Vale TG, Matos FJ. Hypoglycemic and anti-lipemic effects of the aqueous extract from *Cissussicyoides*. BMC Pharmacol, 2004;8:4-9.
10. Huralikuppi JC. Antidiabetic effect of *Nelumbonucifera* extract: Part 2. Phytother. Res. 1991;5:217-223.
11. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355:2427–2443.
12. Khunti K, Davies M. Glycaemic goals in patients with type 2 diabetes: Current status, challenges and recent advances. Diabetes ObesMetab. 2010;12:474–484.
13. Weidmann P, Boehlen LM, De-courten M. Pathogenesis and treatment of hypertension associated with diabetes mellitus. Am Heart J.1993;125:1498-1513.
14. Prince PSM, Menon VP, Pari L. Hypoglycaemic activity of *Syzygiumcumini* seeds: effect on lipid peroxidation in alloxan diabetic rats. J Ethnopharmacol. 1998;61:1-7.
15. Malviya N, Jain S, Malviya S. Antidiabetic potential of medicinal plants. Acta Pol Pharm. 2010;67(2):113–118.
16. Hui H, Tang G, Liang VW, Go VLW. Hypoglycemic herbs and their action mechanisms. Chin Med. 2009;4:11-14.
17. Rozenberg K, Rosenzweig T. *Sarcopoterium spinosum* extract improved insulin sensitivity in mice models of glucose intolerance and diabetes. PLoS One. 2018;16;13(5):e0196736.
DOI:10.1371/journal.pone.0196736
eCollection 2018. PubMed
PMID: 29768504.
18. Paarakh PM, Patil LJ, Thanga SA. Genus Salacia: A Comprehensive Review. JNR: 2008;8/2:116-131.
19. Ogbonna DN, Sokari TG, Agomuoh AA. Antimalarial activities of some selected traditional herbs from Southeastern Nigeria against *Plasmodium* species. J Parasitol Res.2008;3(1):25-31.
20. Obadoni BO, Ochuko PO. Phytochemical studies and comparative efficacy of some haemostatic plants in Edo and Delta States of Nigeria. GJPAST. 2001;8:203-208.
21. Harbone, J. B. Phytochemical Methods- A guide to Modern techniques of Plant Analysis. 3rd edition. Thompson Press limited. New Delhi; 2005.
22. Kareru PG. Ethnomedicine practices, analysis and standardization of herbal anthelmintic drug used by Embu and Mbeere Peoples of Kenya. PhD. Jomo Kenyatta University of Agriculture and Technology. Juja. Kenya; 2008.
23. Rahmatullah M, Sultan S, Toma TT, Safa SL, Chowdhury MH, Haque WM, Jahan R. Effect of *cuscuta reflexa* stem and *calotropis procera* leaf extracts on glucose tolerance in glucose induced hyperglycemic rats and mice. Afr. J. Trad. CAM. 2010;7:109–112.
24. Lorke D. A new approach for practical acute toxicity testing. Arch. Toxicol. 1983;275-287.
25. Edem DO. Hypoglycaemic effects of ethanolic extracts of alligator pear seed (*Persea Americana* Mill) in Rats. Eur. J. Sci. Res. 2009;33(4):669-678.
26. Varley H. Practical clinical biochemistry. 4th ed. Delhi, India: CBS Publishers and Distributors.1988;84.
27. Sonwane P, Navghare V, Ingole P, Pawale S, Khadbadi S, Gond N. Antidiabetic activity of *AcalyphaIndica* Linn in Alloxan Induced Diabetic Rats, Indo Am J Pharm Edu: 2013;3:9.
28. Marsh WH, Fingerhut B, Miller H. Automated and manual direct methods for the determination of blood urea. Clin Chem.1965;11:624–627.
29. Brod J, Sirota JH. J. clin. Invest.1948;27: 645.
30. Mohun AF, Cook IJY. J. Clin. Path. 1957; 10:394.
31. King EJ, Armstrong AR. A convenient method for determining serum and bile phosphatase activity, Can. Med. Assoc. J. 1934;31:376.
32. Lee RH, et al. Multipotent stromal cells from human marrow home to and promote repair of pancreatic islets and renal glomeruli in diabetic NOD_scid mice. PNAS. 2006;103(46):17438–17443.

33. Fredrickson DS, Levy RI, Lees RS. Fat transport in lipoproteins- An integrated approach to mechanisms and disorders. *Nutr Rev.* 2009;45:271-273.
34. Ghoghari AM, Rajani M. Densitometric determination of hecogenin from *Agave americana* leaf using HPTLC. *Chromatografia.* 2006;64: 113-116.
35. Panda S, Kar A. Annonasquamosa seed extract in regulation of hyperthyroidism and lipid Peroxidation in mice: possible involvement of quercetin. *Phytomedicine.* 2007;14:799-805.
36. Sofowora A. Medicinal plants and traditional medicine in Africa, 3rd Edition. John Wiley and sons Ltd. New York. 2008; 199-202.
37. Eze ED, Mohammed A, Musa KY, Tanko Y AS, Isa AS. Effect of Ethanolic leaf extract of *Mucunapruriens* (fabaceae) on Lipid Profile in Alloxan-Induced Diabetic Wistar rats. *Br. J. Pharmacol. Toxicol.* 2012;3(3): 102-109.
38. Ojelabi BA, Areola JO, Babalola OO. Roles of *Glyphaeabrevis* (Spreng) extract in cadmium induced hepatocellular damage and oxidative stress in rabbit. *J. Biotechnol. Pharm. Res.* 2012;3(7):123-128.
39. Dooka BD, Ezejiofor AN. antidiabetic and cytoprotective effect of ethanolic extract of *Salacianitida* root on alloxan-induced diabetic rats. *J Pharm. BiolSci.* 2017;87-93.
40. Marles RJ, Farnsworth NR. Plants as sources of anti-diabetic agents. In: Wagner H, Farnsworth NR, Eds., *Economic and Medicinal Plant Research*, Academic Press Ltd., London,1994;149-187.
41. Goldner M, Gomori G. Alloxan induced diabetes. *J. Endocrinol.*1943;33:297-299.
42. Etuk E, Mohammed B. Evidence-based analysis of chemical method of induction of diabetes mellitus in experimental animals. *Asian J Exp Biol.* 2010;1:331-336.
43. Adeyi A, Idowu B, Mafiana C, Oluwalana S, Ajayi O, Akinloye O. Rat model of food-induced non-obese-type 2 diabetes mellitus: Comparative pathophysiology and histopathology. *Intl J Physiol Pathophysiol Pharmacol.* 2012;1:51-58.
44. Vivek KS, Suresh K, Hitesh JP, Shivakkumar H. Hypoglycemic activity of *Ficusglomerata* in alloxan-induced diabetic rats. *Int. J. Pharmaceutical Sci. Rev. Res.* 2010;1(2):19.
45. Maiti R, Jana D, Das UK, Ghosh D. Antidiabetic effect of aqueous extract of seed of *Tamarindusindica* in Streptozocin induced diabetic rats. *J Ethnopharmacol.* 2004;2(1):85-91.
46. Chatterjee K, Ali KM, De Debasis, Panda KD, Ghosh D. Antidiabetic and antioxidative activity of ethyl acetate fraction of hydromethanolic extract of seed of *Eugenia jambolana* Linn through *in vivo* and *in vitro* study and its chromatographic purification. *Free Radicals and Antioxidants.* 2012; 2(1): 21-30.
47. Latha S, Rajaram K, Suresh Kumar P. Hepatoprotective and Antidiabetic effect of methanol extract of *Carallumafimbriata* in streptozocin induced diabetic albino rats. *Int J Pharm Pharm Sci.* 2014;6(1).
48. Nakashima N, Kimura I, Kimura M, Matsura H. Isolation of pseudoprotimosaponin AIII from rhizomes of *Anemarrhena asphodeloides* and its hypoglycemic activity in streptozocin-induced diabetic mice. *J Nat Prod.* 1993;56(30):345–350.
49. Bonilla JV, Gilbertsville KY. Methods and Composition for regulation of blood cholesterol. *Afri J Traditional Complement Altern Med.* 2009;6(4):573–578.
50. Sharifi-Rad M, Tayeboon GS, Sharifi-Rad J, Iriti M, Varoni EM, Razazi S. Inhibitory activity on type 2 diabetes and hypertension key-enzymes, and antioxidant capacity of *Veronica persica* phenolic-rich extracts. *Cell MolBiol (Noisy-le-grand).* 2016;62(6):80-5. PubMed PMID: 27262808.
51. Elfellah MS, Akhter MH, Khan MT. Anti-hyperglycemic effect of an extract of *Myrtus communis* in streptozocin-induced diabetes in mice. *J Ethnopharmacol.* 1984;11:275-281.
52. Marles RJ, Farnsworth NR. Antidiabetic plants and their active constituents. *Phytomedicine.* 1995;12:137-165.
53. Alarcon-Aguilara FJ, Roman-Ramos R, Perez-Gutierrez S, Aguilar-Contreras A, Contreras-Weber CC, Flores-Saen JL. Study of the anti-hyperglycemic effect of plants used as antidiabetics. *J. Ethnopharmacol.*1998;61:101–110.
54. Ayaz NO. Antidiabetic and renoprotective effects of water extract of

- Rosmarinus officinalis* in streptozotocin-induced diabetic rat. Afr J Pharm Pharmacol. 2012; 6:2664-2669.
55. Dabaghian FH, Kamalinejad M, Shojaei A, Abdollahi Fard, M. Presenting anti-diabetic plants in Iranian traditional medicine. J Diabetes Endocrinol. 2012;3:70-76.
 56. Arumugam G, Manjula P, Paari N. A review: Anti diabetic medicinal plants used for diabetes mellitus. J Acute Disease. 2013;2:196-200.
 57. Gillespie KM. Type 1 diabetes: Pathogenesis and prevention. CMAJ 175 2006;(2):165–170.
 58. Whitton PD, Hems DA. Glycogen synthesis in perfused liver of streptozotocin diabetic rats. Biochem J.1975;150(2):53–161.
 59. Winarsi H, Sasongko ND, Purwanto A, Arinton IG, Nuraeni I. *In vitro* antioxidant activity of the stem and leaves *Amomum cardamomum* extracts. Proceedings on international conference on medicinal plants Purwokerto: The 43rd National Meeting of National Working Group on Indonesia Medicinal Plant; 2012.
 60. Akbari F, Ansari-Samani R, Karimi A, Mortazaei S, Shahinfard N, Rafeian-Kopaei M. Effect of turnip on glucose and lipid profiles of alloxan-induced diabetic rats. Iran J Endocrinol Metab. 2013;14: 492–497.
 61. Mehrzadi S, Tavakolifar B, Huseini HF, Mosavat SH, Heydari M. The Effects of *Boswellia serrata* gum resin on the blood glucose and lipid profile of diabetic patients: A double-blind randomized placebo-controlled clinical trial. J Evid Based Integr Med. 2018;23: 2515690X18772728. DOI:10.1177/2515690X18772728 PubMed PMID: 29774768
 62. Nimenibo-uadia R. Effect of aqueous extract of *Canavalia ensiformis* seeds on hyperlipidemic and hyperktonaemia in alloxan-induced diabetic rats. Biokemistri. 2003;15:7-15.
 63. Rotimi SO, Omotosho OE, Rotiimi OA. Persistence of acidosis in alloxan induced diabetic rats treated with the juice of *Asystasia gangetica* leaves. Phcog. Mag. 2011;7:25-30.
 64. Jung UJ, Lee MK, Park YB, Kang MA, Choia MS. Effect of *Citrus flavonoids* on lipid metabolism and glucose-regulating enzyme mRNA levels in type 2 diabetic mice. Int J Biochem Cell Biol. 2006;38:1134-1145.
 65. Palvai VR, Urooj A. Inhibition of 3-Hydroxy3-methylglutaryl Coenzyme A Reductase (Ex Vivo) by *Morusindica* (Mulberry). Chinese J Biol; 2014. Article ID 318561, 5 pages. Available:<http://dx.doi.org/10.1155/2014/318561>
 66. Salvamani S, Baskaran G, Noor AS, Siti AA, Mohd YS. Antiatherosclerotic effects of plant Flavonoids. Bio Med Res Int; 2014. Article ID 480258, 11 pages Available:<http://dx.doi.org/10.1155/2014/480258>
 67. Farswan M, Mazumber PM, Percha V. Protective effect of *Cassia glauca* Linn. on the serum glucose and hepatic enzymes level in streptozotocin induced NIDDM in rats. Indian J Pharmacol. 2009;41(1):19-22.
 68. Baron A, Brechtel G, Wallace P, Edelman S. Rates and tissue sites of non-insulin- and insulin-mediated glucose uptake in humans. American Journal of Physiology-Endocrinology and Metabolism. 1988;255: 769–774.
 69. Dame SS. 1981 Drug and the liver: Diseases of the liver and the biliary system. Drugs. 1981;6:295-317.
 70. Yakubu MT, Bilbis LS, Lawal M, Akanji MA. Effect of repeated administration of sildenafil citrate on selected enzyme activities of liver and kidney of male albino rats. Nigerian J. Pure Appl. Sci. Technol. 2003;18(1):1395–1400.
 71. Bhattacharya S, Gachhui R, Sil PC. Effect of Kombucha, a fermented black tea in attenuating oxidative stress mediated tissue damage in alloxan induced diabetic rats. Food Chem Toxicol. 2013;60:328-40.
 72. Ravi K, Sivagnanam K, Subramanian S. Anti-diabetic activity of *Eugenia jambolana* seed kernels on streptozotocin induced diabetic rats. J Med Food. 2004;7(2);187–19.
 73. Iweala EEJ, Uhegbu FO, Adesanoye OA. Biochemical effects of leaf extracts of *Gongronema latifolium* and selenium supplementation in alloxan induced diabetic rats. J. Pharmacognosy Phytother. 2013;5(5):91-97.
 74. Edem DO, Usuh IF. Biochemical changes in Wistar Rats on oral doses of Mistletoe

- (*Loranthus micranthus*). *Am J Pharmacol.* 2009;4(3):94–97.
75. Vasantha kumara V, Shyamaladevi CS. Biochemical evaluation of Tara Keswara Rasa- An Antidiabetic drug- in Rats. *Indian Drugs.* 1998;35:140-143.
76. Whitby LG, Smith AF, Becket GJ. Lecture notes on clinical chemistry 9th ed. Blackwell Scientific Publications, Oxford. London, Edinburgh, Boston, Melbourne;1989.

© 2018 Zawua and Kagbo; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:
The peer review history for this paper can be accessed here:
<http://www.sciencedomain.org/review-history/25583>